Evidence map›Paper›PMID 42630733›Full record

ReviewUS cardiology2026

Beyond Hyperglycemia: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction.

Rebecca S Steinberg, Ritika Tuli, Shivani Reddy, Rafael Toro-Manotas, Natalie Marrero, Dinu V Balanescu, Manu Murali Mysore

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in US cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rebecca S SteinbergDepartment of Medicine, Division of Cardiovascular Disease, Duke University School of Medicine Durham, NC.ORCID https://orcid.org/0000-0003-4622-626X
Ritika TuliCardioNerds Academy, CardioNerds Baltimore, MD.ORCID https://orcid.org/0009-0006-5918-5136
Shivani ReddyCardioNerds Academy, CardioNerds Baltimore, MD.ORCID https://orcid.org/0000-0003-4046-1795
Rafael Toro-ManotasCardioNerds Academy, CardioNerds Baltimore, MD.ORCID https://orcid.org/0000-0002-0946-9468
Natalie MarreroCardioNerds Academy, CardioNerds Baltimore, MD.ORCID https://orcid.org/0009-0006-1938-9679
Dinu V BalanescuCardioNerds Academy, CardioNerds Baltimore, MD.
Manu Murali MysoreDepartment of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine Baltimore, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent data suggest that sodium-glucose cotransporter 2 inhibitors have cardioprotective benefits. This effect may extend towards cardioprotection in cancer therapy-related cardiac dysfunction, with proposed mechanisms extending beyond glycemic control to include anti-inflammatory effects, oxidative stress reduction, and metabolic reprogramming. This review synthesizes potential mechanisms, observational data, and emerging trial evidence to support sodium-glucose cotransporter 2 inhibitors as a primary prevention strategy for cancer therapy-related cardiac dysfunction, particularly in anthracycline-exposed populations.

Indexed as

cancer treatment-related cardiac dysfunctioncardioprotectionprimary preventionsecondary preventionSodium–glucose cotransporter 2 inhibitor

Identifiers

PMID42630733
PMCPMC13495110

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.